thiazol-5-ylmethyl N-[(1S,4S)-1-benzyl-4-[[(2S)-3-methyl-2-[[methyl(thiazol-4-ylmethyl)carbamoyl]amino]butanoyl]amino]-5-phenyl-pentyl]carbamate | 1562429-43-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: thiazol-5-ylmethyl N-[(1S,4S)-1-benzyl-4-[[(2S)-3-methyl-2-[[methyl(thiazol-4-ylmethyl)carbamoyl]amino]butanoyl]amino]-5-phenyl-pentyl]carbamate
• 英文别名: 1,3-thiazol-5-ylmethyl N-[(2S,5S)-5-[[(2S)-3-methyl-2-[[methyl(1,3-thiazol-4-ylmethyl)carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
• CAS: 1562429-43-9
• 化学式: C₃₄H₄₂N₆O₄S₂
• 分子量: 662.877
• InChiKey: RXXJTASWFDWOMQ-QYDYLWNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  46
• 可旋转键数：
  17
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  182
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N-甲基-1-(1,3-噻唑-4-基)甲胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 thiazol-5-ylmethyl N-[(1S,4S)-1-benzyl-4-[[(2S)-3-methyl-2-[[methyl(thiazol-4-ylmethyl)carbamoyl]amino]butanoyl]amino]-5-phenyl-pentyl]carbamate
  参考文献：
  名称：

  Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)

  摘要：

  The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer with other classes of anti-HIV agents. Ritonavir is also associated with limitations such as poor physicochemical properties. To address these issues a series of compounds with replacements at the P2 and/or P3 region was designed and evaluated as novel CYP3A inhibitors. Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.057

文献信息

• Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)
  作者：Lianhong Xu、Hongtao Liu、Allen Hong、Randy Vivian、Bernard P. Murray、Christian Callebaut、You-Chul Choi、Melody S. Lee、Jennifer Chau、Luong K. Tsai、Kirsten M. Stray、Robert G. Strickley、Jianhong Wang、Leah Tong、Swami Swaminathan、Gerry R. Rhodes、Manoj C. Desai

  DOI：10.1016/j.bmcl.2013.12.057

  日期：2014.2

  The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer with other classes of anti-HIV agents. Ritonavir is also associated with limitations such as poor physicochemical properties. To address these issues a series of compounds with replacements at the P2 and/or P3 region was designed and evaluated as novel CYP3A inhibitors. Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered. (C) 2013 Elsevier Ltd. All rights reserved.